

**Public Communication -  
Health Canada Endorsed Important Safety Information on  
VOTRIENT® (pazopanib hydrochloride)**



August 9, 2013

**Subject: VOTRIENT® (pazopanib hydrochloride) - Important Change to Frequency of Liver Test Monitoring for Liver Toxicity**

GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of an important safety update to the Warnings & Precautions section of the Product Information for VOTRIENT®, regarding a change in frequency for monitoring liver toxicity.

- VOTRIENT® may cause liver damage. VOTRIENT® should not be used in patients with moderate or severe liver impairment (reduced function), or in patients with certain changes in liver blood tests done prior to taking VOTRIENT®.
- Testing for liver problems during treatment has increased to include monitoring during weeks 2, 4, 6, 8 and Months 3 and 4, and at the recommendation of your doctor. Regular monitoring should continue after Month 4.
- Contact your doctor if you are taking VOTRIENT® and have any questions about this safety update and how it could affect your treatment.

VOTRIENT® is used in the treatment of metastatic kidney cancer (when cancer cells have spread from the kidney to other parts of the body). VOTRIENT® is also used for certain types of advanced soft tissue sarcoma in patients who have already received chemotherapy. Soft tissue sarcoma is a type of cancer that occurs in muscles, blood vessels or other tissues that support, surround and protect the body's organs.

GlaxoSmithKline has sent a letter to healthcare professionals informing them of this new safety information. This information can be obtained on the Canadian website of GlaxoSmithKline ([www.gsk.ca](http://www.gsk.ca)) or on the Health Canada Web site ([healthycanadians.gc.ca/index-eng.php](http://healthycanadians.gc.ca/index-eng.php)). If you have questions regarding your VOTRIENT® prescription, please contact your doctor.

For media inquiries, please contact GlaxoSmithKline Communications at (905) 819-3363.

Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any serious or unexpected side effects in patients receiving VOTRIENT® should be reported to GlaxoSmithKline Inc. or Health Canada.

GlaxoSmithKline Inc.  
7333 Mississauga Road  
Mississauga, Ontario  
L5N 6L4

Phone: 1-800-387-7374

You can report any suspected adverse reactions associated with the use of health products to Health Canada by:

- Calling toll-free at 1-866-234-2345; or
- Visiting MedEffect Canada's Web page on [Adverse Reaction Reporting](http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php) (<http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php>) for information on how to report online, by mail or by fax

For other health product inquiries related to this communication, please contact Health Canada at:

Marketed Health Products Directorate  
E-mail: [mhpd\\_dpsc@hc-sc.gc.ca](mailto:mhpd_dpsc@hc-sc.gc.ca)  
Telephone: 613-954-6522  
Fax: 613-952-7738

Sincerely,

*Original signed by*

Dr. Glenn Crater  
Vice President, Medical and Chief Medical Officer  
GlaxoSmithKline Inc.

VOTRIENT® is a registered trademark, used under license by GlaxoSmithKline Inc.